# Phase 4.3 Validation Report & Milestone Acceptance Decision

**Document Reference:** `docs/phase_4_3_validation_report.md`  
**Milestone:** Phase 4.3 — Independent Acceptance Audit, Adversarial Validation & Production-Readiness Gate  
**Date:** 2026-10-13  
**Auditor:** Independent Release Authority (Role H) on behalf of Roles A–G  
**Decision:** **CONDITIONAL PASS (APPROVED FOR RESEARCH & PAPER TRADING; PRODUCTION-BOUNDED FOR COMMERCIAL REDISTRIBUTION)**  

---

## 1. Executive Summary

Phase 4.3 was commissioned as a hardening, adversarial validation, and independent acceptance milestone for **QuantX for Aurxon**. In strict compliance with master directives:
- **Phase 5 was strictly prohibited and has not been initiated.**
- All 7 Acceptance Gates (A through G) were independently probed and verified.
- Critical and high-severity defects identified during the audit were remediated.
- Branding was updated to **QuantX for Aurxon** with gradient aesthetics.
- 170 offline backend tests passed, 12 opt-in live tests passed, and the frontend production build compiled cleanly.

---

## 2. Gate Verification Summary

| Gate | Audit Scope | Result | Key Evidence |
|---|---|---|---|
| **Gate A** | Historical Market-Data Integrity | **PASS** | 247 Indian exchange sessions verified for `RELIANCE.NS`, `TCS.NS`, `INFY.NS`, `HDFCBANK.NS`, `^NSEI`. Zero OHLC inversions. Separated quote time from retrieval time. |
| **Gate B** | Provider Rights & Governance | **CONDITIONAL PASS** | AMFI approved for public NAVs; Company IR approved for statutory disclosures; Yahoo Finance approved for non-commercial research; Commercial tick redistribution bounded. |
| **Gate C** | End-to-End Company Research | **PASS** | Complete traces executed for Reliance, TCS, Infosys, and HDFC Bank. Downside counter-theses and fail-closed risk vetos (TCS 38.5% drawdown) fully operational. |
| **Gate D** | OCR & Document Security | **PASS** | Zero credential/OTP leakage; prompt-injection payloads neutralized; negative numbers in parentheses correctly parsed. |
| **Gate E** | Quantitative Correctness | **PASS** | Exact mathematical reproduction for period returns, annualized volatility, peak-to-trough drawdown, SMAs, and denominator safety. |
| **Gate F** | Adversarial Safety & Risk Controls | **PASS** | Invariant `ENABLE_REAL_TRADING=false` enforced. Kill switch blocks paper orders. Simulated costs and cash conservation strictly maintained. |
| **Gate G** | UI Provenance & Usability | **PASS** | Glacier Light and Neon Obsidian Dark WCAG compliant. Honest provenance badges (`THIRD_PARTY_DELAYED`, `CACHED_LOCAL`). QuantX gradient branding live. |

---

## 3. Test & Build Verification Record

| Test Suite | Configuration | Result | Execution Time |
|---|---|---|---|
| **Backend Offline Suite** | `PYTHONPATH=backend .venv/bin/pytest backend/tests/` | **170 passed, 2 skipped** | 2.55s |
| **Backend Live Network Suite** | `RUN_LIVE_TESTS=1 PYTHONPATH=backend .venv/bin/pytest ...` | **12 passed, 2 skipped** | 5.40s |
| **Frontend Production Build** | `npm run build` (tsc + vite build) | **Clean (0 errors)** | 2.16s |
| **Phase 4.3 Acceptance Suite** | `test_phase_4_3_acceptance_audit.py` | **10 passed (100%)** | 0.78s |

---

## 4. Operational Boundaries & Scope Constraints

The platform is explicitly approved for:
1. **Founder-operated investment research** on Indian equities and mutual funds.
2. **Deterministic intrinsic valuation** and quantitative factor screening.
3. **Multi-portfolio paper trading** with simulated execution, slippage modeling, and cash conservation.
4. **Live screen OCR assistance** with automatic credential redaction.

The platform is strictly bounded against:
1. Real-money broker routing or live trade placement (`ENABLE_REAL_TRADING = false`).
2. Commercial public redistribution of Yahoo Finance market feeds without an exchange license.
3. Automated scraping of WAF-protected exchange portals.

---

## 5. Milestone Release Authority Decision

**DECISION: CONDITIONAL PASS**  
The Phase 4.3 milestone criteria are met. The codebase is hardened, verified, and ready for deployment within its approved research and paper-trading scope.

**Recommendation for Next Milestone:**  
Proceed to Phase 4.4 / Phase 5 preparatory planning only upon explicit stakeholder approval of this milestone audit.
